Shots: Regenxbio to receive up front, development and commercial milestone and royalties on sales of products. Pfizer to get non-exclusive WW license with rights to sublicense Regenxbio’s NAV AAV9 vector to […]readmore
Tags : NAV AAV9 vector
Shots: RegenxBio to receive $7M upfront, milestones payments plus royalties on net sales. Rocket to get exclusive worldwide rights for RegenxBio’s NAV AAV9 Vector to develop and commercialize gene therapies […]readmore
Shots: Regenxbio to get $100M as total deal value plus $20M upfront ($10M paid on signing, $10M with 12 mos.) in addition to $60M milestone payment on sales Abeona to […]readmore